• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 19, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Naltrexone helps HIV positive individuals reduce heavy alcohol use

Bioengineer by Bioengineer
August 7, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New Haven, Conn. – Extended-release naltrexone — an injection that decreases heavy drinking in the general population when taken in conjunction with counseling — appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers.

This study was published online on Aug. 2 in AIDS and Behavior.

"While we know that patients with heavy alcohol use are less likely to take their medications for HIV, there is a paucity of interventions that target alcohol use to improve how patients take their medications," said Jennifer Edelman, M.D., first author and associate professor at the Yale School of Medicine. "Extended-release naltrexone is a medication that is safe and effective for patients living with HIV that can be delivered in HIV treatment settings that could potentially help this problem."

Conducted between April 2011 and February 2015, the trial involved 51 HIV positive individuals who exhibited heavy drinking and suboptimal (less than 95%) antiretroviral adherence. All the participants in the study received counseling. Researchers found that the extended-release naltrexone led to clinically and statistically significant decreases in the number of heavy drinking days for the participants.

However, the researchers saw no appreciable effect of the extended-release naltrexone, versus a placebo, on the adherence of HIV-positive individuals to their antiretroviral therapy regimens.

"We hope that these results will stimulate further research focused on enhancing the coupling of alcohol interventions with antiretroviral medication adherence interventions to improve both alcohol use and HIV related outcomes," said Lynn Fiellin, M.D., senior author, director of the Yale Center for Health and Learning Games, and associate professor at the Yale School of Medicine.

###

Other authors on this study include Brent A. Moore, Stephen R. Holt, Nathan Hansen, Tassos C. Kyriakides, Michael Virata, Sheldon Brown, Amy C. Justice, Kendall J. Bryant, and David A. Fiellin.

This study was funded by the U.S. National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism.

Aids and Behavior DOI: 10.1007/s10461-018-2241-z

Media Contact

Kendall Teare
[email protected]
203-836-4226
@yale

http://www.yale.edu

http://dx.doi.org/10.1007/s10461-018-2241-z

Share12Tweet7Share2ShareShareShare1

Related Posts

Targeting Lipid Metabolism to Enhance Antitumor Immunity

September 19, 2025

Uncovering Gaps in Rehab for Hospitalized Patients

September 19, 2025

Collaborating on European Data Science for Seniors

September 19, 2025

Intraoperative Ventilation Approaches for Thoracic Surgery

September 19, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    155 shares
    Share 62 Tweet 39
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Physicists Develop Visible Time Crystal for the First Time

    67 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Olefin π-Coordination at Low-Oxidation Boron Centers

Targeting Lipid Metabolism to Enhance Antitumor Immunity

Triple Wavefront Modulation Enables Advanced Multi-Depth XR Vision

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.